Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center, randomized, double-blind, and active-controlled confirmatory phase 3 clinical trial for Enavogliflozin as a triple combination therapy with Metformin and Gemigliptin in patients with type 2 diabetes

Next Previous
Trial Profile

A multi-center, randomized, double-blind, and active-controlled confirmatory phase 3 clinical trial for Enavogliflozin as a triple combination therapy with Metformin and Gemigliptin in patients with type 2 diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enavogliflozin (Primary) ; Dapagliflozin; Gemigliptin; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms ENHANCE-D
  • Sponsors Daewoong Pharmaceutical

Most Recent Events

  • 01 Jul 2023 Primary endpoint has not been met, (change in HbA1c from baseline to week 24), as per published in the Diabetes and Metabolism
  • 01 Jul 2023 Results evaluating the efficacy and safety of enavogliflozin versus dapagliflozin in Korean patients with type 2 diabetes mellitus , published in the Diabetes and Metabolism
  • 01 Nov 2022 According to a Daewon Pharmaceutical media release, data presented at the 2022 International Congress of Diabetes and Metabolism (2022 ICDM).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top